CLAIMS

1. A composition comprising the following components:

component (I), cilostazol, a pharmaceutically acceptable salt, or a stereoisomer thereof; and

component (II), (+)-2-borneol, or borneol.

2. The composition according to claim 1, wherein the component (I) and the component (II) are in a weight ratio of 100:1-1:1.

3. The composition according to claim 1, wherein the component (I) and the component (II) are in a weight ratio of 50:1-1:1.

4. The composition according to claim 1, wherein the component (I) and the component (II) are in a weight ratio of 36:1-1:1.

5. The composition according to claim 1, wherein the component (I) and the component (II) are in a weight ratio of 36:1-3:1.

6. The composition according to claim 1, wherein the component (I) and the component (II) are in a weight ratio of 18:1-3:1.

7. The composition according to claim 1, wherein the component (I) and the component (II) are in a weight ratio of 9:1-3:1.

8. The composition according to claim 1, wherein the component (I) and the component (II) are in a weight ratio of 1:1, 3:1, 9:1, 10:1 and/or 18:1.

9. A drug, comprising the composition according to any one of claims 1 to 8, and a pharmaceutically acceptable adjuvant.

10. Use of the composition according to any one of claims 1 to 8 or the drug according to claim 9 in the manufacture of a medicament for preventing and/or treating cerebrovascular diseases.

11. The use according to claim 10, wherein the cerebrovascular disease is selected from ischemic cerebrovascular disease.

12. The use according to claim 11, wherein the ischemic cerebrovascular disease is selected

from ischemic stroke.